Eyelid Tumor, Keratosis, Pigmented Nevi, Xanthelasma Palpebrarum
Conditions
Brief summary
This study aims to assess the long-term efficacy and safety of ultrapulse carbon dioxide (CO₂) laser excision in the treatment of eyelid tumors, including xanthelasma, pigmented nevi, keratoses, and so on.
Detailed description
-Background: The assessment of the efficacy and safety of Ultrapulse CO₂ laser in treating eyelid lesions is crucial for clinical applications. This study aims to evaluate the effectiveness of super-pulsed CO₂ laser in treating different types of eyelid lesions, particularly marginal and large lesions, to provide comprehensive clinical guidance and decision support. -Main Objectives: A retrospective analysis of the efficacy and safety of Ultrapulse CO₂ laser treatment for various types of eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on. -Study Design: This study will include 1000 patients diagnosed with eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on. All patients undergoing Ultrapulse CO₂ laser treatment. The evaluation will focus on the efficacy and safety of Ultrapulse CO₂ laser treatment for different types of eyelid lesions. -Study Population and Anticipated Enrollment: Patients with eyelid lesions (n=1000) -Inclusion Criteria: Clinically diagnosed with eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on. No history of photosensitivity, bleeding, or coagulation disorders Willing to attend follow-up appointments as scheduled -Exclusion Criteria: Presence of infection in the target area Allergy to lidocaine Keloid-prone or poor skin repair ability Pregnant or lactating Recent history of severe infectious diseases, active skin diseases, or major diseases affecting the cardiovascular, liver, kidney, endocrine, and hematopoietic systems History of malignant tumors or immune system disorders
Interventions
PROCEDUREUltra-pulsed Carbon Dioxide Laser
Excision of eyelid lesion
Sponsors
Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Clinically diagnosed with eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on. * No history of photosensitivity, bleeding, or coagulation disorders * Willing to attend follow-up appointments as scheduled
Exclusion criteria
* Presence of infection in the target area * Allergy to lidocaine * Keloid-prone or poor skin repair ability * Pregnant or lactating * Recent history of severe infectious diseases, active skin diseases, or major diseases affecting the cardiovascular, liver, kidney, endocrine, and hematopoietic systems * History of malignant tumors or immune system disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clearance rate | 12 months | The lesion clearance rate was classified as the proportion of the lesion cleared (\<50%; 50-75%; 76-99%; or \>99%). |
| Recurrence rate | 12 months | Recurrence was defined as the regrowth of a new xanthelasma lesion within the previously excised area. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative complications | 12 months | Lesion recurred, minor trichiasis, partial sparse to absent eyelashes, hypertrophic scar, hyperpigmentation |
| Investigator's Global Assessment (IGA) score | 12 months | Investigator's Global Assessment (IGA) score for measuring improvement in clinical outcomes: 1=worsened; 2=no change; 3=minor improvement; 4=moderate improvement; 5=marked improvement; 6=near-total improvement; and 7=total improvement. |
| Patient satisfaction score | 12 months | Patient satisfaction was evaluated subjectively by the physician on a f ve-point scale, as follows: 0=no change; 1=minor improvement; 2=moderate improvement; 3=marked improvement; 4=near-total or total improvement. |
| Number of treatment sessions | 12 months | Number of treatment sessions for complete clearance |
Countries
China
Contacts
Primary ContactDingqiao Wang, PhD
Outcome results
None listed